Jordan, K., Jahn, F., Jahn, P., Behlendorf, T., Stein, A., Ruessel, J., … Schmoll, H. J. (2011). The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: Paclitaxel, ifosfamide, carboplatin, etoposide): Efficacy and safety of a triple antiemetic combination. Bone Marrow Transplantation, 46(6), 784–789.
To assess the role of an neurokinin 1 (NK1) antagonist in antimetic protection in combination with granisetron and dexamethasone in patients receiving high-dose chemotherapy (HDC)
This study was conducted at a single site at a university hospital in Halle, Germany.
This was a nonrandomized, single-center, observational trial.
The study demonstrated a good toxicity profile with the addition of aprepitant to the standard antiemetic regimen, with improvement in the prevention of chemotherapy-induced nausea and vomiting (CINV) during multiday, high-dose regimens.